副神经节瘤最新研究进展
Recent Research Progress of Paraganglioma
DOI: 10.12677/ACM.2021.119590, PDF,   
作者: 常正松：青海大学研究生院，青海 西宁；张易青*：青海大学附属医院病理科，青海 西宁
关键词: 副神经节瘤；嗜铬细胞瘤；SHDB；SSTR2；Paraganglioma； Pheochromocytoma； SDHB； SSTR2
摘要: 副神经节瘤(Paraganglioma)是一种源于胚胎时期残留在体内的神经嵴源性副神经节细胞的神经内分泌肿瘤，可发生于全身各处，但在肾上腺和颈动脉体周围多见。随着研究的进展，曾被人们视为良性的副神经节瘤现被认为是一种恶性肿瘤，其复发及转移的机制成为了研究的热点。本文旨在对副神经节瘤的分类、相关基因及治疗的研究进行复习，为未来对其的更进一步研究打下相应理论基础。
Abstract: Paraganglioma is a kind of neuroendocrine tumor which derived from neural crest derived paraganglion cells remaining in the body during embryonic stage. It can induce all over the body, but it is common around the adrenal gland and carotid body. With the progress of research, paraganglioma, once regarded as benign, is now considered as a malignant tumor. The mechanism of recurrence and metastasis has become a research hotspot. This paper aims to review the classification, related genes and treatment of paraganglioma, so as to lay a corresponding theoretical foundation for further research in the future.
文章引用：常正松, 张易青. 副神经节瘤最新研究进展[J]. 临床医学进展, 2021, 11(9): 4048-4053. https://doi.org/10.12677/ACM.2021.119590

参考文献

[1] 赵华, 王凯, 王鸿雁, 郑建杰. 心脏副神经节瘤1例并文献复习[J]. 诊断病理学杂志, 2020, 27(8): 564-566+572.
[2] Thompson, L.D.R. (2006) World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. ENT Journal, 85, 427-437. [Google Scholar] [CrossRef] [PubMed]
[3] 刘彤华, 诊断病理学[M]. 第3版. 北京: 人民卫生出版社, 428-429.
[4] 方三高, 魏建国, 周晓军. WHO (2017)肾上腺肿瘤分类解读[J]. 诊断病理学杂志, 2018, 25(12): 801-806.
[5] Thompson, L.D.R. (2002) Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign from Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases. The American Journal of Surgical Pathology, 26, 551-566. [Google Scholar] [CrossRef] [PubMed]
[6] Noriko, K., Ryoichi, T., Nae, T., Eiji, I., Takayuki, K., Narihiko, K., Hiromi, R., Yukihiro, I., Akiyo, T., Takeshi, N., Sadayoshi, I., Itaru, K. and Mitsuhide, N. (2014) Pathological Grading for Predicting Metastasis in Phaeochromocytoma and Paraganglioma. Endocrine-Related Cancer, 21, 405-414. [Google Scholar] [CrossRef] 
[7] Niu, F., Li, Y., Lai, F.-F. and Chen, X.-G. (2014) [Research Progress of Hypoxia-Inducible Factor 1 Inhibitors against Tumors]. Acta Pharmaceutica Sinica, 49, 832-836.
[8] Peng, S., Zhang, J., Tan, X., Huang, Y., Xu, J., Silk, N., Zhang, D., Liu, Q. and Jiang, J. (2020) The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma. Frontiers in Endocrinology, 11, Article ID: 586857. [Google Scholar] [CrossRef] [PubMed]
[9] Bausch, B., Wellner, U., Bausch, D., et al. (2014) Long-Term Prognosis of Patients with Pediatric Pheochromocytoma. Endocrine-Related Cancer, 21, 17-25. [Google Scholar] [CrossRef] 
[10] Lefebvre, M. and Foulkes, W.D. (2014) Pheochromocytoma and Paraganglioma Syndromes: Genetics and Management Update. Current Oncology, 21, e8-e17. [Google Scholar] [CrossRef] [PubMed]
[11] 石穿, 曾正陪, 赵大春, 李汉忠, 苗齐, 朱文玲, 陈适, 卢琳, 梁志勇. 琥珀酸脱氢酶B、C免疫组化在鉴别良恶性嗜铬细胞瘤和副神经节瘤中的应用[J]. 中华内分泌代谢杂志, 2018, 34(6): 472-478.
[12] Lucinda, G. and James, M.L. (2021) Predicted Succinated Dehydrogenase Subunit Variant Pathogenicity: Why Are SDHB Variants “Bad”? Journal of the Endocrine Society, 5, A71-A72. [Google Scholar] [CrossRef] 
[13] 车金娜. 潜在恶性嗜铬细胞瘤的临床特征分析及SDHB、SDHD的相关研究[D]: [硕士学位论文]. 青岛: 青岛大学, 2020.
[14] Cui, Y., Ma, X., Wang, F., Wang, H., Zhou, T., Chen, S., Tong, A. and Li, Y. (2021) Differences in Clinical Manifestations and Tumor Features between Metastatic Pheochromocytoma/Paraganglioma Patients with and without Germline SDHB Mutation. Endocrine Practice, 27, 348-353. [Google Scholar] [CrossRef] [PubMed]
[15] Dahia, P.L.M. (2014) Pheochromocytoma and Paraganglioma Pathogenesis: Learning from Genetic Heterogeneity. Nature Reviews Cancer, 14, 108-119. [Google Scholar] [CrossRef] [PubMed]
[16] Tarade, D., Robinson, C.M., Lee, J.E. and Ohh, M. (2018) HIF-2α-pVHL Complex Reveals Broad Genotype-Phenotype Correlations in HIF-2α-Driven Disease. Nature Communications, 9, Article No. 3359. [Google Scholar] [CrossRef] [PubMed]
[17] Xiong, Z., Xiong, W., Xiao, W., Yuan, C., Shi, J., Huang, Y., Wang, C., Meng, X., Chen, Z., Yang, H., Chen, K. and Zhang, X. (2021) NNT-Induced Tumor Cell “Slimming” Reverses the Pro-Carcinogenesis Effect of HIF2a in Tumors. Clinical and Translational Medicine, 11, e264. [Google Scholar] [CrossRef] [PubMed]
[18] C. Bellevicine, I. Migliatico, R. Sgariglia, M. Nacchio, E. Vigliar, P. Pisapia, et al. (2020) Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg Alterations in Different Bethesda Diagnostic Categories: A Multicentric Prospective Study on the Validity of the 7-Gene Panel Test in 1172 Thyroid FNAs Deriving from Different Hospitals in South Italy. Cancer Cytopathology, 128, 107-118. [Google Scholar] [CrossRef] [PubMed]
[19] Erika, M., Floriana, M., Teresa, T. and Fortunato, C. (2017) Cancer Resistance to Therapies against the EGFR-RAS-RAF Pathway: The Role of MEK. Cancer Treatment Reviews, 53, 61-69. [Google Scholar] [CrossRef] [PubMed]
[20] Vari, S., Pilotto, S., Maugeri-Saccà, M., Ciuffreda, L., Incani, U.C., Falcone, I., et al. (2013) Advances towards the Design and Development of Personalized Non-Small-Cell Lung Cancer Drug Therapy. Expert Opinion on Drug Discovery, 8, 1381-1397. [Google Scholar] [CrossRef] [PubMed]
[21] 张婷婷, 邓丽玲, 邓明彦, 任艳. 2例多发性内分泌腺瘤病2A型家系临床分析及RET基因突变研究[J]. 四川大学学报(医学版), 2019, 50(5): 757-759.
[22] Pan, Y., Hysinger, J.D., Barron, T., Schindler, N.F., Cobb, O., Guo, X., et al. (2021) NF1 Mutation Drives Neuronal Activity-Dependent Initiation of Optic Glioma. Nature, 594, 277-282. [Google Scholar] [CrossRef] [PubMed]
[23] Habulieti, X., Sun, L., Liu, J., Guo, K., Yang, X., Wang, R., Ma, D. and Zhang, X. (2021) Phenotypic and Genetic Characterization of Novel Variant in the NF1 Gene Underlying Neurofibromatosis Type 1 in Five Chinese Families. Science China Life Sciences, 1-4. http://kns.cnki.net/kcms/detail/11.5841.Q.20210513.1311.002.html [Google Scholar] [CrossRef] [PubMed]
[24] Patel, D., Phay, J.E., Yen, T.W.F., Dickson, P.V., Wang, T.S., Garcia, R., et al. (2020) Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. Annals of Surgical Oncology, 27, 1329-1337. [Google Scholar] [CrossRef] [PubMed]
[25] 卢梦杰. 人源生长抑素II型受体(SSTR2)的结构生物学研究[D]: [博士学位论文]. 上海: 中国科学院大学(中国科学院上海药物研究所), 2019.

为你推荐